Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiotaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked how Parkinson's disease and its medications reshape the fecal bacterial community. Researchers sequenced the V4 and V5 regions of the bacterial 16S rRNA gene on an Ion Torrent PGM platform. They compared patients with healthy controls and tested the influence of L-dopa and the COMT inhibitor entacapone. Fecal calprotectin, a marker of gut inflammation, was measured to link inflammation with specific taxa. PICRUSt predicted metabolic pathway diversity from the sequence data.
Who was studied?
The cohort was 34 Parkinson's disease patients (10 female, 24 male) and 25 age-matched healthy controls (14 female, 11 male) in Germany. Fecal samples were collected in 2015. Mean patient age was 67.9 years and mean control age was 63.9 years. All patients took dopaminergic drugs, with mean disease duration of 82 months and a median Hoehn and Yahr stage of 2.5. All subjects were omnivores with no reported recent antibiotics or gastrointestinal disorders.
What were the most important findings?
Patients showed significantly lower alpha diversity than controls for observed and estimated species (p = 0.032), while beta diversity did not differ. One family and three genera differed in relative abundance. Clostridiales family XI members increased in patients, including opportunistic genera such as Peptoniphilus, Anaerococcus and Finegoldia. Anti-inflammatory butyrate producers such as Faecalibacterium decreased, especially in patients with elevated calprotectin. L-dopa treatment shifted several genera, and entacapone was linked to the largest number of significantly altered families and genera versus controls.
What are the greatest implications of this study?
The findings suggest Parkinson's medications, not just the disease, drive measurable changes in gut bacteria. This complicates efforts to define a disease-specific microbiome signature. A decline in butyrate producers alongside a rise in opportunistic taxa could plausibly relate to gut inflammation and barrier changes reported in Parkinson's disease. The authors stress these are associations. Causal links between the disease, drug treatment and the microbiota remain unresolved and need functional, geographically diverse studies.